Chimerix.

 
FREE EXCERPT

* Biopharmaceutical company Chimerix raised nearly $35 million in equity to buy the exclusive global rights to a leukemia treatment. Chimerix has agreed to acquire the worldwide license of CX-01 from Florida's Cantex Pharmaceuticals. Chimerix will pay Cantex $30 million...

To continue reading

FREE SIGN UP